Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.31 |
| ▸ | GLRB | P48167 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183640 | 0.91 | DRD2 (0.43) | JAK1DRD2SLC6A4JAK2TYK2 | |
| SCHEMBL10183158 | 0.91 | DRD2 (0.43) | JAK1DRD2SLC6A4JAK2TYK2 | |
| SCHEMBL10235416 | 0.90 | JAK1 (0.34) | JAK1DRD2SLC6A4JAK2TYK2 | |
| SCHEMBL10183281 | 0.86 | SYK (0.35) | JAK1DRD2SLC6A4JAK2TYK2 | |
| SCHEMBL10183230 | 0.85 | GLRA3 (0.35) | DRD2SLC6A4GLRA3GLRBEGFR | |
| SCHEMBL10183626 | 0.83 | EGFR (0.40) | JAK1DRD2SLC6A4EGFRIDO1 | |
| SCHEMBL10183244 | 0.82 | IDO1 (0.35) | GLRA3GLRBEGFRIDO1 | |
| SCHEMBL10183124 | 0.81 | EGFR (0.42) | JAK1JAK2JAK3EGFR | |
| SCHEMBL10183143 | 0.81 | GAA (0.44) | JAK1JAK2JAK3EGFR | |
| SCHEMBL10183285 | 0.80 | ALDH1A1 (0.46) | JAK1JAK2TYK2JAK3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | JAK1 941/4885DRD2 4814/4885SLC6A4 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.